Louise Chen
Stock Analyst at Scotiabank
(0)
# 3069
Out of 5,291 analysts
342
Total ratings
43.11%
Success rate
3.45%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Sarepta Therapeutics | Maintains: Sector Perform | 105 80 | 70.41 | 13.62% | 2 | Mar 20, 2025 | |
Gain Therapeutics | Initiates Coverage On: Sector Outperform | 12 | 1.88 | 538.3% | 1 | Mar 7, 2025 | |
Innoviva | Initiates Coverage On: Sector Outperform | 55 | 18.18 | 202.53% | 5 | Mar 7, 2025 | |
Blueprint Medicines | Initiates Coverage On: Sector Outperform | 150 | 88.69 | 69.13% | 1 | Mar 7, 2025 | |
PTC Therapeutics | Initiates Coverage On: Sector Perform | 55 | 54.18 | 1.51% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 15 | 2.21 | 578.73% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 50 | 27.84 | 79.6% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 15 | 4.92 | 204.88% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 17 | 6.45 | 163.57% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 70 | 31.59 | 121.59% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 50 | 11.46 | 336.3% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 30 | 12.49 | 140.19% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 15 | 1.59 | 843.4% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 50 | 23.27 | 114.87% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sector Outperform | 55 | 37.28 | 47.53% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 160 160 | 69.36 | 130.68% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 45 45 | 25.19 | 78.64% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 215 215 | 163.6 | 31.42% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 155 155 | 89.18 | 73.81% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 885 885 | 820.02 | 7.92% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 200 200 | 205.15 | -2.51% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 925 925 | 637.75 | 45.04% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 65 65 | 7.58 | 757.52% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 | n/a | n/a | 4 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 5 | 0.73 | 584.93% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 | 0.82 | 2948.78% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 | 15.25 | 227.87% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 20 | n/a | n/a | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 | 15.73 | 217.86% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 18 1 | n/a | n/a | 7 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 5 | 0.96 | 420.83% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 5 9 | 1.69 | 432.54% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 33 21 | n/a | n/a | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 1 | n/a | n/a | 3 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 1200 80 | n/a | n/a | 2 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 5 2 | n/a | n/a | 2 | May 6, 2022 |